Major PBMs Inflated Drug Prices, Pocketing $7.3 Billion Along the Way, FTC Says
The three largest pharmacy benefit managers (PBMs) inflated the price of specialty generic drugs beyond their costs of acquisition, earning more than $7.3 billion in revenue from 2017 to 2022, according to a report issued by the Federal Trade Commission (FTC) on Tuesday.
On Tuesday, the Federal Trade Commission released its second interim staff report on prescription drug middlemen. The report ...
Andrew Witty, UnitedHealth CEO, said the move will remove an excuse other players use to blame Optum Rx for high drug costs.
Hosted on MSN10m
UnitedHealth's OptumRx Accused of Excessive Drug PricingThe Federal Trade Commission accused UnitedHealth's OptumRx, CVS Caremark, and Cigna's Express Scripts of pocketing over $7 ...
Futurism on MSN2h
Insurance Company Where CEO Was Assassinated Jacking Up Cost of Cancer Drugs by "Thousands of Percent," Government FindsUnitedHealthcare's legal drug dealing arm is, according to the government, massively marking up the cost of life-saving ...
A bill before the Arkansas legislature would prevent pharmacy benefit managers (PBMs) or insurance companies from obtaining ...
Mattingly is an associate professor and vice chair of research in the Department of Pharmacotherapy at the University of Utah ...
The Massachusetts Democrat is working with a Missouri Republican, and House members from each party, to press the FTC to ...
The pharmaceutical supply chain is a sector infamous for glacially slow adjustments, lackluster reform, lack of transparency ...
The pharmaceutical industry, grappling with new government limits on drug prices, is focusing its requests for ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback